Treatment algorithms of relapsing multiple sclerosis: an exploration based on the available disease-modifying therapies in China

Author:

Guo Jun1ORCID,Wu Jiayong2,Wang Lihua3,Liu Hongbo4,Wu Xiaomu5,Yang Huan6ORCID,Li Wenyu7,Wang Honghao8,Bu Bitao9,Yang Chunsheng10ORCID,Zhou Hongyu11,Guo Shougang12,Zhao Yinan13,Wang Zhanhang14,Li Chunyang15,Tian De-Cai16,Chen Sheng17,Xue Huiru18,Zhang Yanlin19,Xu Yongfeng20ORCID,Liang Hui21,Wu Zhe22,Zhang Yu23,Dong Qiang2425,Wang Jiawei26,Quan Chao2725ORCID

Affiliation:

1. Department of Neurology, Tangdu Hospital, Air Force Medical University, Xi’an, China

2. Department of Neurology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China

3. Department of Neurology, The Second Affiliated Hospital, Harbin Medical University, Harbin, China

4. Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

5. Department of Neurology, The First Affiliated Hospital of Nanchang University, Nanchang, China

6. Department of Neurology, Xiangya Hospital, Central South University, Changsha, China

7. Department of Neurology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China

8. Department of Neurology, Guangzhou First People’s Hospital, Guangzhou, China

9. Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

10. Department of Neurology, Tianjin Medical University General Hospital, Tianjin, China

11. Department of Neurology, West China Hospital, Sichuan University, Chengdu, China

12. Department of Neurology, Shandong Provincial Hospital, Shandong First Medical University, Jinan, China

13. Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China

14. Department of Neurology, Guangdong 999 Brain Hospital, Guangzhou, China

15. Department of Neurology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China

16. Center for Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

17. Department of Neurology & Institute of Neurology, Ruijin Hospital, Affiliated with Shanghai Jiao Tong University School of Medicine, Shanghai, China

18. Department of Neurology, First Hospital of Shanxi Medical University, Taiyuan, China

19. Department of Neurology, Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

20. Department of Neurology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China

21. Department of Neurology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

22. Department of Neurology, The First Hospital of China Medical University, Shenyang, China

23. Biogen, Shanghai, China

24. Department of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China

25. National Center for Neurological Disorders, Shanghai, China

26. Department of Neurology, Beijing Tongren Hospital, Capital Medical University, Beijing, China

27. Department of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, No. 12, Middle Wulumuqi Road, Shanghai 200040, China

Abstract

Multiple sclerosis (MS) was defined as a rare disease in China due to its low prevalence. For a long time, interferon β was the only approved disease-modifying therapy (DMT). Since the first oral DMT was approved in 2018, DMT approval accelerated, and seven DMTs were approved within 5 years. With an increasing number of DMTs being prescribed in clinical practice, it is necessary to discuss the standardized MS treatment algorithms depending on the disease activity and DMT availability. In this review paper, more than 20 Chinese experts in MS have reviewed the therapeutic progress of MS in China and worldwide and discussed algorithms for treating relapsing MS (RMS) based on the available DMTs in China, providing insights for establishing the standardized RMS treatment algorithms in this country.

Funder

National Natural Science Foundation of China

Shanghai Municipal Health Commission

Publisher

SAGE Publications

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3